British Companies Nix Challenge to New Cost-effectiveness Rules

International Pharmaceutical Regulatory Monitor
A A
The trade association of the British drug industry dropped its legal challenge to new guidelines from national regulators that subject higher-priced drugs to an extra review under England’s single-payer National Health Service.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor